Advertisement

Topics

With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production

11:09 EDT 31 Jul 2017 | Genetic Engineering News

Chimeric antigen receptor T-cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently-awarded patent. Cesca said Friday that U.S. Patent No. 9,695,394, titled “Cell Separation Devices, Systems, and Methods,” has been awarded to SynGen—whose cell processing assets were acquired earlier this month by Cesca’s 80%-owned device subsidiary ThermoGenesis. The patented technology relates to automated isolation of rare stem, progenitor or immune cell populations from blood, bone marrow, leukapheresis product, and other sources, while maintaining the viability of the cells under asceptic conditions. The patented technology has been incorporated into Cesca’s proprietary CAR-TXpress™ platform, designed to integrate multi-component automation steps that include T-cell isolation, purification, culture expansion and washing, and single cassette-based automated -196°C cryopreservation and retrieval. Cesca says its automated cell processing system provides greater cell yields ...

Original Article: With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production

NEXT ARTICLE

More From BioPortfolio on "With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production"

Quick Search
Advertisement